The Science Behind Mounjaro: What Tirzepatide Actually Does in Your Body

You've heard it called a 'hunger jab', here's what's really happening

Most people arrive at the question of tirzepatide's science from a specific moment: a friend lost a significant amount of weight, or a GP mentioned it, or they read a headline that made it sound almost too simple. The reality is more interesting than the shorthand suggests.

Your gut produces two hormones after you eat, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both are released in response to food; both send signals that tell the brain you've eaten and tell the pancreas to manage blood sugar. In people carrying excess weight, those signals often become blunted over time. Tirzepatide is a synthetic molecule engineered to mimic and amplify both of them at once. No other licensed weight-loss medicine in the UK does this. Older GLP-1 medicines activate one pathway; Mounjaro activates two. You can explore the wider tirzepatide evidence base, including our overview of Peptide Sciences tirzepatide, on our tirzepatide overview page.

The practical result people notice first is not dramatic, it tends to be a quieting of the mental noise around food. The near-constant background awareness of hunger that many people describe simply becomes less loud. Portions that would previously have felt frustratingly small start to feel genuinely sufficient. If you want to understand what this shift feels like day to day, our guide to the Mounjaro experience walks through what patients typically notice at each stage of treatment.

One useful habit: before each weekly injection, take thirty seconds to note how hungry you actually felt that week compared with the week before. It is a low-effort way to track whether the medicine is doing what it should, and useful information to share with your prescriber at review.

What slowed gastric emptying means for the experience of eating

Beyond appetite signalling, both GIP and GLP-1 pathways contribute to slowing gastric emptying, the rate at which your stomach passes food into the small intestine. This is part of why meals feel more filling for longer on tirzepatide. It also explains most of the common side effects.

When food lingers in the stomach longer than usual, especially early in treatment or after a dose increase, nausea is the predictable response. Diarrhoea, constipation, indigestion and burping are all part of the same picture. For most people these effects are most pronounced in the first few weeks and ease as the body adapts. Our collection of real Mounjaro experiences from people at different stages of treatment covers this more personally.

The titration schedule (starting at 2.5 mg and stepping up under prescriber guidance) exists precisely because of gastric emptying. A slower increase gives the gut time to adjust. The NHS's medicines information for tirzepatide explains the side-effect profile in plain language alongside the full NHS medicines page for tirzepatide, which is worth bookmarking for reference.

It is also worth knowing that slowed gastric emptying can reduce the absorption speed of oral medicines taken at the same time. Women on oral contraceptives starting tirzepatide are advised to use an additional non-oral method for the first four weeks of treatment and for four weeks after each dose increase. Our page on Mounjaro and nutritional considerations touches on some related absorption questions that patients raise.

The trial evidence and what the science translates to in practice

The SURMOUNT clinical programme is the body of evidence behind Mounjaro's approval. SURMOUNT-1 randomised 2,539 adults with obesity (without diabetes) and, at the 15 mg dose over 72 weeks, recorded average weight reductions of around 20–21%. The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, ran tirzepatide head-to-head against semaglutide 2.4 mg and found tirzepatide produced greater average weight reduction. NICE reviewed this evidence in its appraisal of tirzepatide (TA1026, published December 2024) and recommended it within defined NHS eligibility criteria.

These are trial averages. Individual responses vary, and the science does not translate cleanly into a personal prediction. What the mechanism does explain is why the medicine tends to work: it addresses two of the biological systems that regulate body weight, not through willpower or restriction alone, but by shifting the hormonal signals that have, for many people, been working against them for years.

Weight is shaped by biology more than most public conversation acknowledges. Tirzepatide does not override that biology, it works with it. For a broader look at how this fits into a wider approach to weight management, the weight-loss treatment overview on our site sets out what clinical support looks like alongside the medicine.

If you are thinking about whether this science translates into something that might suit your situation specifically, a prescriber is the right person to ask. Our team at nume... At nume, every consultation is read personally by a GPhC-registered Independent Prescriber (a real clinician, not a decision tree) and reviewed the same day. Cost context is useful to consider early too; the guide to obtaining Mounjaro through a private pharmacy explains what a legitimate private prescription typically involves. If you have questions before starting, the FAQs cover the most common ones, and you can always reach our team directly.